ArticleClinical ophthalmology (Auckland, N.Z.)2012
Insight into 144 patients with ocular vascular events during VEGF antagonist injections.
Article in Clinical ophthalmology (Auckland, N.Z.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- Two or more dexamethasone intravitreal implants as monotherapy or in combination therapy for macular edema in retinal vein occlusion: subgroup analysis of a retrospective chart review study.BMC ophthalmology · 2015Trial
- Systemic and ocular complications related to intravitreal administration of anti-VEGF agents.Medical hypothesis, discovery & innovation ophthalmology journal · 2026Review
- Central retinal vein occlusion following intravitreal injections: a case series highlighting multifactorial risk.International journal of retina and vitreous · 2025Article
- A retrospective, cross-sectional analysis of the dental status and needs of patients taking vascular endothelial growth factor (VEGF) antagonists.Clinical oral investigations · 2025Article
- Non-Arteritic Anterior Ischemic Optic Neuropathy (NA-AION): A Comprehensive Overview.Vision (Basel, Switzerland) · 2023Review
- Risk of transient vision loss after intravitreal aflibercept using vial-prepared vs. the novel prefilled syringe formulation.Frontiers in medicine · 2023Article
- Three Monthly Injections Versus One Initial Injection of Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion: 12-Month Results of a Prospective Randomized Study.Ophthalmology and therapy · 2022Article
- Optical coherence tomography angiography analysis of changes in the foveal avascular zone in eyes with diabetic macular edema treated with intravitreal anti-vascular endothelial growth factor.International journal of retina and vitreous · 2022Article
- Survey of Intravitreal Injection Techniques and Treatment Protocols Among Members of the Turkish Ophthalmological Association.Turkish journal of ophthalmology · 2021Article
- Branch retinal artery occlusion in the untreated contralateral eye following aflibercept injections during heparin treatment: Possible contribution of a heparin-induced thrombocytopenia-like condition.American journal of ophthalmology case reports · 2019Article
- The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy.Central-European journal of immunology · 2016Review
- A Single Intravitreal Injection of Ranibizumab Provides No Neuroprotection in a Nonhuman Primate Model of Moderate-to-Severe Nonarteritic Anterior Ischemic Optic Neuropathy.Investigative ophthalmology & visual science · 2015Article
- Transient retinal artery occlusion during phacoemulsification cataract surgery.Eye (London, England) · 2015Article
- Diabetic Macular Edema: From Old Concepts to New Therapeutic Avenues.Medical hypothesis, discovery & innovation ophthalmology journal · 2015Review
- Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy.Eye (London, England) · 2015Article
- Short-term intraocular pressure changes after intravitreal injection of bevacizumab in diabetic retinopathy patients.Clinical ophthalmology (Auckland, N.Z.) · 2014Article
- Unilateral branch retinal arterial occlusion following administration of bevacizumab for branch retinal vein occlusion.International ophthalmology · 2013Article
- Changes in the foveal microstructure after intravitreal bevacizumab application in patients with retinal vascular disease.Clinical ophthalmology (Auckland, N.Z.) · 2013Article
- Marked Choroidal Thinning Observed after Intravitreal Brolucizumab Injection.Case reports in ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo record ocular vascular events following injections of vascular endothelium growth factor (VEGF) antagonists.
methodsCollaborative multicenter case series (48 cases), literature reviews (32 cases), and reports to the FDA (64 cases) of patients that had vascular occlusions during anti-VEGF therapy were collected and analyzed.
resultsA total of 144 cases of ocular vascular events were identified, with these diagnosed a median of 15 days after anti-VEGF injection. The majority of patients had pre-existing risk factors for cardiovascular events and nine patients had a prior history of glaucoma. Mean visual acuity dropped by 6.4 lines with severe visual loss after injection to NLP (five eyes), LP (six eyes), and HM (two eyes). The overall risk of ocular vascular events following a VEGF antagonist injection was 0.108% in the general population and 2.61% in the diabetic population. Mean retinal arterial constriction after intravitreal bevacizumab in 13 eyes was 21% (standard deviation = 27%), and mean retinal venous constriction was 8% (standard deviation = 30%).
conclusionOcular vascular events are rare during anti-VEGF therapy, but can lead to severe visual loss and may be caused by a number of factors including the vasoconstrictor effect of the drug, a post-injection rise of intraocular pressure, patient stress as a result of the procedure, and the patient's natural history of underlying ocular or systemic diseases. The diabetic population appears to have a tendency towards ocular vascular occlusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.